https://www.pharmaradar360.com/article/secret-contracts-reveal-undisclosed-terms-in-trump-s-drug-pricing-deals-bcbb413fb30f9d63PharmaRadar360en2026-09-19T10:05:32.000ZSecret contracts reveal undisclosed terms in Trump’s drug-pricing dealshttps://www.pharmaradar360.com/article/tirupati-group-appoints-uday-k-potdar-as-chief-financial-officer-339f006e241d5b8dPharmaRadar360en2026-09-19T10:01:43.000ZTirupati Group Appoints Uday K. Potdar As Chief Financial Officerhttps://www.pharmaradar360.com/article/medicine-shortages-deepen-in-iran-amid-war-shipping-restrictions-1722387ef29ee867PharmaRadar360en2026-09-19T08:18:00.000ZMedicine shortages deepen in Iran amid war, shipping restrictionshttps://www.pharmaradar360.com/article/fda-approves-imlunestrant-plus-abemaciclib-for-esr1-mutated-breast-cancer-3c625593f647ec48PharmaRadar360en2026-09-19T06:37:48.000ZFDA approves imlunestrant plus abemaciclib for ESR1-mutated breast cancerhttps://www.pharmaradar360.com/article/alumna-employs-biotech-to-create-sustainable-livestock-production-f241526028de166dPharmaRadar360en2026-09-19T06:00:00.000ZAlumna employs biotech to create sustainable livestock productionhttps://www.pharmaradar360.com/article/iraq-customs-clarifies-duties-on-pharmaceuticals-vitamins-and-supplements-8cc25463c2e436b0PharmaRadar360en2026-09-19T05:09:34.000ZIraq Customs clarifies duties on pharmaceuticals, vitamins, and supplementshttps://www.pharmaradar360.com/article/pharmtech-weekly-roundup-september-18-2026-177f47cf9e1b228bPharmaRadar360en2026-09-19T05:03:45.000ZPharmTech Weekly Roundup—September 18, 2026https://www.pharmaradar360.com/article/how-annex-1-upgrades-at-west-pharmaceutical-services-wst-have-changed-its-invest-c6d42c01254a7c15PharmaRadar360en2026-09-19T02:42:21.000ZHow Annex 1 Upgrades At West Pharmaceutical Services (WST) Have Changed Its Investment Storyhttps://www.pharmaradar360.com/article/fda-hearing-psychedelics-launch-needs-balanced-regulation-without-limiting-acces-81cc63fd87c8c2d5PharmaRadar360en2026-09-19T02:15:00.000ZFDA hearing: psychedelics launch needs balanced regulation without limiting accesshttps://www.pharmaradar360.com/article/homilia-te-deum-una-casa-edificada-sobre-roca-470e28c9f1d5d8c9PharmaRadar360en2026-09-19T00:08:42.000ZHomilía Te Deum: Una casa edificada sobre rocahttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-92f3d478f9a9a803PharmaRadar360en2026-09-19T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-30d05734be2b8565PharmaRadar360en2026-09-19T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-22ff2a568dabf918PharmaRadar360en2026-09-19T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-de70afab94ee6db7PharmaRadar360en2026-09-19T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-f1fd06fc7a374965PharmaRadar360en2026-09-19T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-27c52285a30f9bc6PharmaRadar360en2026-09-19T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-8f9e69afd0cb053dPharmaRadar360en2026-09-19T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-efef70c7d026f41bPharmaRadar360en2026-09-19T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-8afc627e4579d5d4PharmaRadar360en2026-09-19T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-e5df46ac20c2e888PharmaRadar360en2026-09-19T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-be70b46a60b900cdPharmaRadar360en2026-09-19T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-e267ca8d0ce77a01PharmaRadar360en2026-09-19T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-b34380177a22639aPharmaRadar360en2026-09-19T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-ef59172569822192PharmaRadar360en2026-09-19T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/safe-medicine-storage-and-disposal-among-pharmacy-and-engineering-students-a-kap-e3e2d4de32f25ed1PharmaRadar360en2026-09-19T00:00:00.000ZSafe Medicine Storage and Disposal among Pharmacy and Engineering Students: A Kap Study with Pre-Post Knowledge Assessmenthttps://www.pharmaradar360.com/article/regenerative-medicine-in-the-management-of-musculoskeletal-pain-mechanisms-clini-d650a4d034f3b544PharmaRadar360en2026-09-19T00:00:00.000ZRegenerative Medicine in the Management of Musculoskeletal Pain: Mechanisms, Clinical Applications, and Future Directionshttps://www.pharmaradar360.com/article/clinical-efficacy-of-minimally-invasive-technologies-in-the-treatment-of-obstruc-b2e082ddcb04ca29PharmaRadar360en2026-09-19T00:00:00.000ZCLINICAL EFFICACY OF MINIMALLY INVASIVE TECHNOLOGIES IN THE TREATMENT OF OBSTRUCTIVE JAUNDICE ASSOCIATED WITH CHOLEDOCHOLITHIASIShttps://www.pharmaradar360.com/article/the-role-of-physicians-in-child-and-adolescent-psychiatry-exploring-the-therapeu-95303ae91b93ede6PharmaRadar360en2026-09-19T00:00:00.000ZThe Role of Physicians in Child and Adolescent Psychiatry: Exploring the Therapeutic Potential of Herbal Remedieshttps://www.pharmaradar360.com/article/examination-of-international-strategies-and-collaborative-efforts-in-responding-dcbf1a1c7f477fb6PharmaRadar360en2026-09-19T00:00:00.000ZExamination of International Strategies and Collaborative Efforts in Responding to the Ebola Crisis in West Africa: Lessons from the 2026 Bundibugyo Outbreak in the Democratic Republic of the Congo and Ugandahttps://www.pharmaradar360.com/article/serum-nfl-and-gfap-levels-and-their-association-with-anxiety-depression-in-alzhe-38114244d078d939PharmaRadar360en2026-09-19T00:00:00.000ZSerum NfL and GFAP levels and their association with anxiety-depression in Alzheimer’s disease patients: A clinical retrospective studyhttps://www.pharmaradar360.com/article/takotsubo-syndrome-a-review-of-psychobiological-mechanisms-and-clinical-practice-796f14de12226badPharmaRadar360en2026-09-19T00:00:00.000ZTakotsubo syndrome: A review of psychobiological mechanisms and clinical practice interventionshttps://www.pharmaradar360.com/article/from-correlation-to-intervention-translating-the-psychological-network-of-adoles-b02a37b1b055f61ePharmaRadar360en2026-09-19T00:00:00.000ZFrom correlation to intervention: Translating the psychological network of adolescent non-suicidal self-injury into clinical practicehttps://www.pharmaradar360.com/article/lt-b-gt-thiet-lap-ca-hai-tham-so-cua-bieu-o-kiem-soat-noi-kiem-hanh-lang-can-tre-a089bde4f7254a16PharmaRadar360en2026-09-19T00:00:00.000Z<b>THIẾT LẬP CẢ HAI THAM SỐ CỦA BIỂU ĐỒ KIỂM SOÁT NỘI KIỂM: HÀNH LANG CẬN TRÊN-CẬN DƯỚI CỦA ĐỘ KHÔNG CHỤM CHO GIỚI HẠN VÀ ĐỐI CHIẾU NGOẠI KIỂM CHO TRUNG BÌNH - NGHIÊN CỨU TRÊN 24 XÉT NGHIỆM HOÁ SINH</b>https://www.pharmaradar360.com/article/lt-b-gt-khao-sat-chi-so-triglyceride-glucose-lt-b-gt-lt-b-gt-tyg-lt-b-gt-lt-b-gt-9aa3330e763554d0PharmaRadar360en2026-09-19T00:00:00.000Z<b>KHẢO SÁT CHỈ SỐ TRIGLYCERIDE-GLUCOSE</b><b> (TYG)</b><b> VÀ MỐI LIÊN QUAN VỚI MỘT SỐ </b><b></b> <b>ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG Ở BỆNH NHÂN GOUT </b><b></b>https://www.pharmaradar360.com/article/proenkephalin-penkid-in-renal-dysfunction-an-integrative-review-of-laboratory-an-93660ff9cfd11b01PharmaRadar360en2026-09-19T00:00:00.000ZProenkephalin/penKid in renal dysfunction: An integrative review of laboratory and clinical evidencehttps://www.pharmaradar360.com/article/regenerative-medicine-at-the-crossroads-of-innovation-evidence-and-clinical-resp-05677a7f689b1c65PharmaRadar360en2026-09-19T00:00:00.000ZRegenerative medicine at the crossroads of innovation, evidence, and clinical responsibilityhttps://www.pharmaradar360.com/article/inguinal-hernia-as-a-systemic-enzyme-dysfunction-disorder-a-prospective-comparat-e64f9953548400b0PharmaRadar360en2026-09-19T00:00:00.000ZInguinal Hernia as a Systemic Enzyme Dysfunction Disorder: A Prospective Comparative Study on the Role of Matrix Metalloproteinase-9 in The Transversalis Fasciahttps://www.pharmaradar360.com/article/the-psychological-impact-of-covid-19-and-mental-relaxation-practices-by-amateur-073b7c79da9ccae2PharmaRadar360en2026-09-19T00:00:00.000ZThe Psychological Impact of COVID -19 and Mental Relaxation Practices by Amateur Boxers: A Qualitative Studyhttps://www.pharmaradar360.com/article/ethnomedicinal-utilization-of-rauwolfia-serpentina-l-benth-ex-kurz-7d5ee8c80c1d7646PharmaRadar360en2026-09-19T00:00:00.000ZEthnomedicinal utilization of Rauwolfia serpentina (L.) Benth. ex Kurzhttps://www.pharmaradar360.com/article/computational-exploration-revealed-nicotiflorin-as-a-potent-dpp4-inhibitor-for-d-5a77b6dc254be1b5PharmaRadar360en2026-09-19T00:00:00.000ZComputational exploration revealed Nicotiflorin as a potent DPP4 inhibitor for diabetes management: Insights from network pharmacology, molecular docking, and molecular dynamics simulations studieshttps://www.pharmaradar360.com/article/development-and-validation-of-a-reverse-phase-high-performance-liquid-chromatogr-ec3e92366fb1a9cePharmaRadar360en2026-09-19T00:00:00.000ZDevelopment and Validation of A Reverse Phase High Performance Liquid Chromatography (Rp-Hplc) Method for The Estimation of Process Related Impurity from Lobeglitazone Sulfatehttps://www.pharmaradar360.com/article/citrate-versus-heparin-anticoagulation-during-crrt-with-mg350-hemoadsorption-in-fd82283ab4495bfcPharmaRadar360en2026-09-19T00:00:00.000ZCitrate versus heparin anticoagulation during CRRT with MG350 hemoadsorption in critically ill patients: a randomized controlled trial protocolhttps://www.pharmaradar360.com/article/clinical-profile-and-treatment-outcomes-of-pleural-effusion-and-empyema-thoracis-bbe452d5da9517d3PharmaRadar360en2026-09-19T00:00:00.000ZClinical Profile and Treatment Outcomes of Pleural Effusion and Empyema Thoracis in a Tertiary Hospital of Bangladeshhttps://www.pharmaradar360.com/article/clinical-correlation-between-the-severity-of-periodontitis-and-alzheimer-s-disea-48dd87cd72f1219bPharmaRadar360en2026-09-19T00:00:00.000ZClinical correlation between the severity of periodontitis and Alzheimer’s disease, along with neuropsychiatric symptoms in the rural populationhttps://www.pharmaradar360.com/article/predicting-hemorrhagic-transformation-in-acute-ischemic-stroke-using-a-machine-l-38c2eae679ddb40bPharmaRadar360en2026-09-19T00:00:00.000ZPredicting hemorrhagic transformation in acute ischemic stroke using a machine learning model based on clinical and HR-MRI featureshttps://www.pharmaradar360.com/article/effects-of-adding-gait-retraining-with-visual-feedback-to-resistance-balance-tra-1e167cbe3a805226PharmaRadar360en2026-09-19T00:00:00.000ZEffects of adding gait retraining with visual feedback to resistance-balance training on kinematics, centers of pressure, and proprioception in individuals with chronic ankle instability: a randomized controlled trialhttps://www.pharmaradar360.com/article/systemic-antibiotic-use-in-paediatric-odontogenic-infections-a-systematic-review-c467c59adf57184aPharmaRadar360en2026-09-19T00:00:00.000ZSystemic antibiotic use in paediatric odontogenic infections: a systematic review of clinical outcomes, prescribing practices, and guideline adherencehttps://www.pharmaradar360.com/article/asymmetrical-bilateral-ureteral-duplication-a-cadaveric-case-report-illustrating-c69d3b4b913c453cPharmaRadar360en2026-09-19T00:00:00.000ZAsymmetrical bilateral ureteral duplication: a cadaveric case report illustrating the clinical implications of a rare congenital urinary tract anomalyhttps://www.pharmaradar360.com/article/minimally-invasive-needle-arthroscopy-versus-conventional-arthroscopy-for-treatm-6fc5da0721eea615PharmaRadar360en2026-09-19T00:00:00.000ZMinimally invasive needle arthroscopy versus conventional arthroscopy for treatment of bacterial knee arthritis: protocol of a pragmatic, multicenter, randomized, controlled, non-inferiority trial (MINA-TRIAL)https://www.pharmaradar360.com/article/self-medication-among-pharmacy-technician-students-in-offa-nigeria-implications-5a745c612e38bddcPharmaRadar360en2026-09-19T00:00:00.000ZSelf-medication among pharmacy technician students in Offa, Nigeria: implications for rational drug use and future healthcare practicehttps://www.pharmaradar360.com/article/school-based-hygiene-intervention-to-prevent-helicobacter-pylori-infection-among-fb3eeb7f9942f557PharmaRadar360en2026-09-19T00:00:00.000ZSchool-based hygiene intervention to prevent Helicobacter Pylori infection among children (SHIP HOPE): a cluster-randomized controlled trialhttps://www.pharmaradar360.com/article/evaluating-a-smartphone-intervention-to-improve-hiv-prevention-and-care-outcomes-bd52996327321260PharmaRadar360en2026-09-19T00:00:00.000ZEvaluating a smartphone intervention to improve HIV prevention and care outcomes: results from the HealthMPowerment national randomized controlled trialhttps://www.pharmaradar360.com/article/efficacy-of-progressive-muscle-relaxation-training-in-post-traumatic-stress-diso-96a07acf7bd3c00aPharmaRadar360en2026-09-19T00:00:00.000ZEfficacy of progressive muscle relaxation training in post-traumatic stress disorder after the Kahramanmaraş earthquake: a randomized controlled trialhttps://www.pharmaradar360.com/article/impact-of-concomitant-grade-i-degenerative-spondylolisthesis-on-clinical-and-rad-b3aa13f3b078fc7dPharmaRadar360en2026-09-19T00:00:00.000ZImpact of Concomitant Grade I Degenerative Spondylolisthesis on Clinical and Radiographic Outcomeshttps://www.pharmaradar360.com/article/care-gaps-following-newly-detected-dipstick-proteinuria-in-treated-hypertension-f6038d0fa7cd35f9PharmaRadar360en2026-09-19T00:00:00.000ZCare Gaps Following Newly Detected Dipstick Proteinuria in Treated Hypertension: A Japanese Nationwide Database Studyhttps://www.pharmaradar360.com/article/systematic-benchmarking-of-evaluation-paradigms-safety-boundaries-and-clinical-r-b9d82694e09b72b9PharmaRadar360en2026-09-19T00:00:00.000ZSystematic benchmarking of evaluation paradigms, safety boundaries, and clinical reasoning gaps for multimodal large language models in rehabilitationhttps://www.pharmaradar360.com/article/thermodynamic-molecular-interdependencies-and-causal-determinants-governing-phar-10f10c771e7ee1bfPharmaRadar360en2026-09-19T00:00:00.000ZThermodynamic–molecular interdependencies and causal determinants governing pharmaceutical solubility in SC-CO2 systemshttps://www.pharmaradar360.com/article/long-term-clinical-outcomes-of-a-hydrofilic-extended-depth-of-focus-intraocular-e572e5d1e90d64cfPharmaRadar360en2026-09-19T00:00:00.000ZLong-Term Clinical Outcomes of a Hydrofilic Extended Depth-of-Focus Intraocular Lenshttps://www.pharmaradar360.com/article/the-impact-of-antihypertensive-de-escalation-a-secondary-analysis-of-systolic-bl-aa5240ab42a1ed19PharmaRadar360en2026-09-19T00:00:00.000ZThe Impact of Antihypertensive De-escalation: A Secondary Analysis of Systolic Blood Pressure Intervention Trial (SPRINT)https://www.pharmaradar360.com/article/sertraline-e9737e737cba8913PharmaRadar360en2026-09-19T00:00:00.000ZSertralinehttps://www.pharmaradar360.com/article/salicylates-50f1ce7783b22311PharmaRadar360en2026-09-19T00:00:00.000ZSalicylateshttps://www.pharmaradar360.com/article/nitrous-oxide-6c11750953e77a2ePharmaRadar360en2026-09-19T00:00:00.000ZNitrous oxidehttps://www.pharmaradar360.com/article/metamfetamine-123bf776ae9e5ebdPharmaRadar360en2026-09-19T00:00:00.000ZMetamfetaminehttps://www.pharmaradar360.com/article/lithium-paracetamol-d20337e1f8385dbePharmaRadar360en2026-09-19T00:00:00.000ZLithium/Paracetamolhttps://www.pharmaradar360.com/article/dicycloverine-0773d3ef428c7525PharmaRadar360en2026-09-19T00:00:00.000ZDicycloverinehttps://www.pharmaradar360.com/article/diamorphine-95e6194fbd91bf71PharmaRadar360en2026-09-19T00:00:00.000ZDiamorphinehttps://www.pharmaradar360.com/article/daptomycin-3c236bfd74a7ae7ePharmaRadar360en2026-09-19T00:00:00.000ZDaptomycinhttps://www.pharmaradar360.com/article/amlodipine-propranolol-fa0af215e5fdd4edPharmaRadar360en2026-09-19T00:00:00.000ZAmlodipine/Propranololhttps://www.pharmaradar360.com/article/deciphering-the-interaction-landscape-of-ndm-1-with-a-novel-lactam-based-inhibit-50512220ed8c509dPharmaRadar360en2026-09-19T00:00:00.000ZDeciphering the interaction landscape of NDM-1 with a novel β-lactam-based inhibitor: implications for rational drug designhttps://www.pharmaradar360.com/article/micellar-systems-with-hydrophobic-core-stabilized-polyethyleneimine-enabling-tim-687784dcfb17eba7PharmaRadar360en2026-09-19T00:00:00.000ZMicellar Systems with Hydrophobic Core-Stabilized Polyethyleneimine Enabling Time-Dependent Positive Zeta Potential Transformation for Enhanced Intestinal Mucopermeation and Cellular Uptakehttps://www.pharmaradar360.com/article/ai-based-smoke-removal-in-robotic-urooncologic-surgery-a-clinical-pilot-study-4053782a128a77b3PharmaRadar360en2026-09-19T00:00:00.000ZAI-based smoke removal in robotic urooncologic surgery: a clinical pilot studyhttps://www.pharmaradar360.com/article/conceptual-growth-curves-of-oropharyngeal-soft-tissues-and-craniofacial-skeletal-d450161164c51a8cPharmaRadar360en2026-09-19T00:00:00.000ZConceptual growth curves of oropharyngeal soft tissues and craniofacial skeletal structures: clinical implications for pediatric airway managementhttps://www.pharmaradar360.com/article/brief-cognitive-behavioral-therapy-for-suicide-prevention-among-racially-and-eth-0036a6580553d84cPharmaRadar360en2026-09-19T00:00:00.000ZBrief Cognitive-Behavioral Therapy for Suicide Prevention Among Racially and Ethnically Minoritized Soldiers: A Secondary Analysis of a Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nature-based-interventions-in-practice-a-scoping-review-of-social-work-literatur-37b90182012c11fcPharmaRadar360en2026-09-19T00:00:00.000ZNature-Based Interventions in Practice: A Scoping Review of Social Work Literaturehttps://www.pharmaradar360.com/article/effectiveness-of-low-level-laser-therapy-in-the-rehabilitation-of-knee-meniscus-d2ca201f02c9cb87PharmaRadar360en2026-09-19T00:00:00.000ZEffectiveness of low-level laser therapy in the rehabilitation of knee meniscus injuries: a randomized, double-blind, placebo-controlled trialhttps://www.pharmaradar360.com/article/integration-of-early-palliative-care-in-cancer-treatment-a-meta-analysis-of-39-r-2e2b33d95289c590PharmaRadar360en2026-09-19T00:00:00.000ZIntegration of early palliative care in cancer treatment: a meta-analysis of 39 randomized controlled trials on clinical outcomes and management optimizationhttps://www.pharmaradar360.com/article/outcomes-of-surgical-intervention-in-retinal-detachment-in-stickler-syndrome-a-s-d4130766d2a7171bPharmaRadar360en2026-09-19T00:00:00.000ZOutcomes of surgical intervention in retinal detachment in stickler syndrome: a systematic review and meta analysishttps://www.pharmaradar360.com/article/analysis-of-brain-volumetry-and-functional-connectivity-during-resting-state-in-eb430aad5af9a35ePharmaRadar360en2026-09-19T00:00:00.000ZAnalysis of brain volumetry and functional connectivity during resting state in patients with borderline personality disorderhttps://www.pharmaradar360.com/article/accelerated-tms-is-associated-with-changes-of-subgenual-cingulate-default-mode-n-8dc272ce8dd99d43PharmaRadar360en2026-09-19T00:00:00.000ZAccelerated TMS is associated with changes of subgenual cingulate–default mode network coupling in depression: an observational 7 Tesla fMRI studyhttps://www.pharmaradar360.com/article/case-based-pharmacotherapeutic-learning-structured-around-the-prescribing-optimi-58d9c0cc03a64972PharmaRadar360en2026-09-19T00:00:00.000ZCase-based pharmacotherapeutic learning structured around the prescribing optimization method and the WHO 6-step model: Medical students’ views from an exploratory questionnaire studyhttps://www.pharmaradar360.com/article/genetically-supported-targets-and-drug-repurposing-for-sleep-disorders-a-mendeli-996bda825dee064aPharmaRadar360en2026-09-19T00:00:00.000ZGenetically supported targets and drug repurposing for sleep disorders: a Mendelian randomization systematic studyhttps://www.pharmaradar360.com/article/from-diagnostic-accuracy-to-clinical-utility-methodological-considerations-on-co-9df4003c012e3774PharmaRadar360en2026-09-19T00:00:00.000ZFrom Diagnostic Accuracy to Clinical Utility: Methodological Considerations on Contrast‐Enhanced Ultrasono‐Distal Cologram in Anorectal Malformationshttps://www.pharmaradar360.com/article/effects-of-continuing-or-withholding-angiotensin-axis-blockers-prior-to-elective-595c845626078b7cPharmaRadar360en2026-09-19T00:00:00.000ZEffects of continuing or withholding angiotensin axis blockers prior to elective surgery: The PAAB randomized clinical trialhttps://www.pharmaradar360.com/article/operationalization-of-the-african-medicines-agency-retrospective-evaluation-of-t-159de1ff28a10a52PharmaRadar360en2026-09-19T00:00:00.000ZOperationalization of the African Medicines Agency: Retrospective evaluation of the continental centralized pilot procedure timelines to recommendation and national registrationshttps://www.pharmaradar360.com/article/retension-pharmaceuticals-trex-bio-file-for-us-ipo-as-biotech-momentum-continues-2f48405acfbfdc68PharmaRadar360en2026-09-18T23:59:53.000ZRetension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continueshttps://www.pharmaradar360.com/article/analysts-think-axsome-therapeutics-stock-could-soar-35-over-the-next-12-months-i-e56809726c192c50PharmaRadar360en2026-09-18T23:02:00.000ZAnalysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?https://www.pharmaradar360.com/article/omnideployment-the-future-of-pharmaceutical-commercialization-1f60f5db440b5bd7PharmaRadar360en2026-09-18T22:53:20.000ZOmnideployment: The Future of Pharmaceutical Commercializationhttps://www.pharmaradar360.com/article/retension-pharmaceuticals-trex-bio-file-for-us-ipo-as-biotech-momentum-continues-9706597300d79daaPharmaRadar360en2026-09-18T22:35:17.000ZRetension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continueshttps://www.pharmaradar360.com/article/the-specter-of-ai-enabled-bioweapons-is-a-wake-up-call-for-biotech-1e7372ba15a5f576PharmaRadar360en2026-09-18T22:28:22.000ZThe specter of AI-enabled bioweapons is a wake-up call for biotechhttps://www.pharmaradar360.com/article/fda-examines-use-of-testosterone-prescriptions-for-menopause-c359720bb3a5c490PharmaRadar360en2026-09-18T22:26:16.000ZFDA examines use of testosterone prescriptions for menopausehttps://www.pharmaradar360.com/article/analysts-think-axsome-therapeutics-stock-could-soar-35-over-the-next-12-months-i-028baa1e5af406d9PharmaRadar360en2026-09-18T22:22:30.000ZAnalysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?https://www.pharmaradar360.com/article/virtual-biotech-company-puts-37-000-ai-agents-to-work-on-drug-discovery-0ab60bbf89b1de5ePharmaRadar360en2026-09-18T22:11:54.000ZVirtual Biotech Company Puts 37,000 AI Agents to Work on Drug Discoveryhttps://www.pharmaradar360.com/article/consulta-publica-requerimientos-tecnicos-administrativos-cb077950f600650aPharmaRadar360en2026-09-18T21:42:36.000ZCONSULTA PÚBLICA REQUERIMIENTOS TÉCNICOS ADMINISTRATIVOShttps://www.pharmaradar360.com/article/trxb-ipo-news-autoimmune-and-inflammatory-diseases-biotech-trex-bio-files-for-a-f91025b93b89cfb7PharmaRadar360en2026-09-18T21:39:00.000ZTRXB IPO News - Autoimmune and inflammatory diseases biotech TRex Bio files for a $100 million IPOhttps://www.pharmaradar360.com/article/mizuho-s-jared-holz-data-doesn-t-show-a-strong-link-between-biotech-and-interest-55a37aa704a9bd07PharmaRadar360en2026-09-18T21:38:00.000ZMizuho's Jared Holz: Data doesn't show a strong link between biotech and interest rateshttps://www.pharmaradar360.com/article/high-throughput-aav-affinity-chromatography-screening-99009d14e786d1a1PharmaRadar360en2026-09-18T21:27:20.000ZHigh-Throughput AAV Affinity Chromatography Screeninghttps://www.pharmaradar360.com/article/mirum-pharmaceuticals-falls-7-1-as-investors-appear-to-reassess-near-term-biotec-1d2cd1c93d265677PharmaRadar360en2026-09-18T21:20:00.000ZMirum Pharmaceuticals Falls 7.1% as Investors Appear to Reassess Near-Term Biotech Catalystshttps://www.pharmaradar360.com/article/white-house-extends-mfn-pricing-to-every-state-medicaid-program-46597a1d0cb97779PharmaRadar360en2026-09-18T21:19:08.000ZWhite House Extends MFN Pricing to Every State Medicaid Programhttps://www.pharmaradar360.com/article/retension-pharmaceuticals-clinical-stage-biopharma-for-hypertension-files-for-na-500bd9025ece2e61PharmaRadar360en2026-09-18T21:18:05.000ZRetension Pharmaceuticals, Clinical-Stage Biopharma for Hypertension, Files for Nasdaq Capital Market IPOhttps://www.pharmaradar360.com/article/moleculin-biotech-disclosed-failure-to-satisfy-a-continued-listing-rule-or-stand-e8243697e82aa9a0PharmaRadar360en2026-09-18T21:03:04.000ZMoleculin Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standardhttps://www.pharmaradar360.com/article/lakewood-amedex-announces-irb-approval-to-initiate-phase-2a-clinical-trial-of-nu-eb20b4f8617ed6baPharmaRadar360en2026-09-18T20:59:00.000ZLakewood-Amedex Announces IRB Approval to Initiate Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcershttps://www.pharmaradar360.com/article/fda-launches-pilot-program-to-speed-early-clinical-trials-e9db1ce137d303a4PharmaRadar360en2026-09-18T20:52:52.000ZFDA Launches Pilot Program to Speed Early Clinical Trialshttps://www.pharmaradar360.com/article/fda-approves-fayuvi-pharmexec-a23663528c3d4358PharmaRadar360en2026-09-18T20:45:47.000ZFDA Approves Fayuvi | PharmExechttps://www.pharmaradar360.com/article/saved-by-wife-s-cpr-bay-area-survivor-leads-heart-walk-to-build-nation-of-lifesa-ec36780d62d0d2bdPharmaRadar360en2026-09-18T20:43:00.000ZSaved by Wife’s CPR, Bay Area Survivor Leads Heart Walk to Build Nation of Lifesavershttps://www.pharmaradar360.com/article/the-biotech-ipo-window-keeps-opening-09264c228e834eaePharmaRadar360en2026-09-18T20:23:46.000ZThe biotech IPO window keeps openinghttps://www.pharmaradar360.com/article/why-this-biotech-just-erased-its-one-day-50-pop-69c3a9008e5f3dadPharmaRadar360en2026-09-18T20:08:00.000ZWhy This Biotech Just Erased Its One-Day 50% Pophttps://www.pharmaradar360.com/article/amneal-announces-fda-approval-and-launch-of-lanreotide-injection-717b592a47d5528fPharmaRadar360en2026-09-18T20:01:00.000ZAmneal Announces FDA Approval and Launch of Lanreotide Injectionhttps://www.pharmaradar360.com/article/novo-nordisk-taps-anthropic-s-claude-to-speed-drug-discovery-6bb9050bfd33342bPharmaRadar360en2026-09-18T19:57:47.000ZNovo Nordisk taps Anthropic's Claude to speed drug discoveryhttps://www.pharmaradar360.com/article/trump-to-announce-all-50-states-joining-medicaid-drug-pricing-model-843f8dad1754e2e8PharmaRadar360en2026-09-18T19:41:54.000ZTrump to announce all 50 states joining Medicaid drug pricing modelhttps://www.pharmaradar360.com/article/vantuil-pereira-e-reconduzido-a-decania-do-centro-de-filosofia-e-ciencias-humana-b4aa1e29c3408934PharmaRadar360en2026-09-18T19:38:00.000ZVantuil Pereira é reconduzido à decania do Centro de Filosofia e Ciências Humanashttps://www.pharmaradar360.com/article/ai-may-kill-us-all-but-biotech-is-the-bigger-threat-to-stocks-cabot-street-check-f6aae46ec1c2910cPharmaRadar360en2026-09-18T19:36:51.000ZAI May Kill Us All. But Biotech Is the Bigger Threat to Stocks | Cabot Street Checkhttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-adds-capital-markets-veteran-as-cfo-while-advancing-bitac-on-a0783c107c82669cPharmaRadar360en2026-09-18T19:30:00.000ZVERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipelinehttps://www.pharmaradar360.com/article/steve-marshall-offers-warning-to-rubio-about-chinese-national-security-threat-in-f029735522effd19PharmaRadar360en2026-09-18T19:05:48.000ZSteve Marshall offers warning to Rubio about Chinese ‘national security threat’ in pharmaceutical supply chainhttps://www.pharmaradar360.com/article/china-plans-to-transform-3m-biotech-sector-into-522b-powerhouse-by-2030-f0565aa05697d5e2PharmaRadar360en2026-09-18T19:05:42.000ZChina plans to transform $3M biotech sector into $522B powerhouse by 2030https://www.pharmaradar360.com/article/insilico-medicine-sehk-3696-advances-rentosertib-into-phase-3-trials-df912cbea33fd048PharmaRadar360en2026-09-18T18:45:19.000ZInSilico Medicine (SEHK:3696) Advances Rentosertib Into Phase 3 Trialshttps://www.pharmaradar360.com/article/fda-issues-food-safety-advisory-for-ganpati-mahaprasad-5cb211e0958c2affPharmaRadar360en2026-09-18T18:42:00.000ZFDA Issues Food Safety Advisory For Ganpati Mahaprasadhttps://www.pharmaradar360.com/article/fda-seizes-593kg-expired-ghee-in-akola-12d85b5806ed4aa9PharmaRadar360en2026-09-18T18:38:00.000ZFDA seizes 593kg expired ghee in Akolahttps://www.pharmaradar360.com/article/xenon-stock-craters-30-on-drug-trial-setback-its-failure-could-be-this-biotech-s-56a2fa84d3bb02c3PharmaRadar360en2026-09-18T18:34:00.000ZXenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.https://www.pharmaradar360.com/article/cordis-project-personalised-medicine-by-using-an-advanced-point-of-care-tool-for-8b4326c6c0ba25ccPharmaRadar360en2026-09-18T18:26:51.000ZCORDIS project: Personalised Medicine by using an Advanced Point-of-Care Tool for Stratified Treatment in High Risk Cardiovascular Patients (PoCCardio)https://www.pharmaradar360.com/article/cordis-project-future-of-alcl-novel-therapies-origins-bio-markers-and-mechanism-27cd89b4f8f7af8cPharmaRadar360en2026-09-18T18:26:38.000ZCORDIS project: Future of ALCL: Novel Therapies, Origins, Bio-Markers and Mechanism of resistancehttps://www.pharmaradar360.com/article/cordis-project-reducing-the-impact-of-major-environmental-challenges-on-mental-h-31bc826d56d240c6PharmaRadar360en2026-09-18T18:26:31.000ZCORDIS project: Reducing the impact of major environmental challenges on mental healthhttps://www.pharmaradar360.com/article/cordis-project-transforming-into-a-sustainable-european-pharmaceutical-sector-28dd3912c72b3695PharmaRadar360en2026-09-18T18:26:30.000ZCORDIS project: Transforming into a sustainable European pharmaceutical sectorhttps://www.pharmaradar360.com/article/cordis-project-understanding-predicting-and-treating-depression-in-pregnancy-to-3a9a37311258eec2PharmaRadar360en2026-09-18T18:26:29.000ZCORDIS project: Understanding, predicting, and treating depression in pregnancy to improve mothers and offspring mental health outcomeshttps://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-appoints-raju-willener-as-cfo-9709b95d0f9b3358PharmaRadar360en2026-09-18T18:03:52.000ZVERAXA Biotech (NASDAQ:VRXA) Appoints Raju Willener as CFOhttps://www.pharmaradar360.com/article/is-this-biotech-stock-too-cheap-to-ignore-after-its-latest-pullback-91f5f5b430dc71f5PharmaRadar360en2026-09-18T18:00:00.000ZIs This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?https://www.pharmaradar360.com/article/first-drug-to-treat-alexander-disease-approved-by-the-fda-after-three-decades-of-34a9482c55fea16cPharmaRadar360en2026-09-18T17:55:04.000ZFirst drug to treat Alexander disease approved by the FDA after three decades of research at UW–Madisonhttps://www.pharmaradar360.com/article/sahpra-reinforces-its-commitment-to-radiation-safety-at-iaea-general-conference-1042c5a1d277999bPharmaRadar360en2026-09-18T17:32:15.000ZSAHPRA Reinforces Its Commitment to Radiation Safety at IAEA General Conferencehttps://www.pharmaradar360.com/article/is-legend-biotech-legn-undervalued-following-its-new-ceo-appointment-a9f1a69f6fd68a4ePharmaRadar360en2026-09-18T17:30:52.000ZIs Legend Biotech (LEGN) Undervalued Following Its New CEO Appointment?https://www.pharmaradar360.com/article/is-this-biotech-stock-too-cheap-to-ignore-after-its-latest-pullback-8a72dc88fe000b4ePharmaRadar360en2026-09-18T17:20:00.000ZIs This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?https://www.pharmaradar360.com/article/beyond-clinical-endpoints-rethinking-als-drug-development-through-disease-biolog-b7cd7818b37e9411PharmaRadar360en2026-09-18T17:15:54.000ZBeyond clinical endpoints: Rethinking ALS drug development through disease biologyhttps://www.pharmaradar360.com/article/montana-opened-a-market-for-experimental-medicines-now-it-should-watch-who-shows-b84ace46a9df7e13PharmaRadar360en2026-09-18T17:14:13.000ZMontana opened a market for experimental medicines. Now it should watch who shows uphttps://www.pharmaradar360.com/article/pune-fda-seizes-adulterated-food-worth-rs-56-36-lakh-banned-gutkha-worth-rs-20-2-b25b754ddcb9cba2PharmaRadar360en2026-09-18T17:08:24.000ZPune FDA Seizes Adulterated Food Worth Rs 56.36 Lakh, Banned Gutkha Worth Rs 20.26 Lakh in Festive Drivehttps://www.pharmaradar360.com/article/post-hoc-live-the-china-biotech-debate-goes-to-washington-601b5ca4af133974PharmaRadar360en2026-09-18T17:08:00.000ZPost-Hoc Live: The China Biotech Debate goes to Washingtonhttps://www.pharmaradar360.com/article/agriculture-studies-networks-for-food-security-agri-net-jica-c3fe72a28b1dd90dPharmaRadar360en2026-09-18T17:04:39.000ZAgriculture Studies Networks for Food Security (Agri-Net) – JICAhttps://www.pharmaradar360.com/article/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say-d48516f28aaf5220PharmaRadar360en2026-09-18T16:54:37.000ZEXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources sayhttps://www.pharmaradar360.com/article/radar-st-84ce3e802a2d1e73PharmaRadar360en2026-09-18T16:52:59.000ZRaDaR® SThttps://www.pharmaradar360.com/article/umd-students-band-together-to-protect-birds-b1696d7be266e817PharmaRadar360en2026-09-18T16:50:32.000ZUMD students band together to protect birdshttps://www.pharmaradar360.com/article/big-lake-agrivoltaics-project-shows-promise-of-mixing-farming-solar-power-e943f5608c414bf6PharmaRadar360en2026-09-18T16:50:01.000ZBig Lake agrivoltaics project shows promise of mixing farming, solar powerhttps://www.pharmaradar360.com/article/umd-engineers-building-brighter-futures-from-duluth-to-kenya-5875172bba4f6965PharmaRadar360en2026-09-18T16:49:16.000ZUMD Engineers building brighter futures from Duluth to Kenyahttps://www.pharmaradar360.com/article/hornets-are-sending-minnesotans-to-the-er-and-into-party-mode-3a7c2094446f40fcPharmaRadar360en2026-09-18T16:48:57.000ZHornets are sending Minnesotans to the ER — and into party modehttps://www.pharmaradar360.com/article/trump-s-authoritarian-mindset-can-t-handle-dissent-from-his-appointees-0f72e70f2f17c74bPharmaRadar360en2026-09-18T16:48:38.000ZTrump’s authoritarian mindset can’t handle dissent from his appointeeshttps://www.pharmaradar360.com/article/glass-pumpkin-patch-at-the-arboretum-d02dfdd728c01c10PharmaRadar360en2026-09-18T16:48:06.000ZGlass Pumpkin Patch at the Arboretumhttps://www.pharmaradar360.com/article/can-ai-agents-satisfy-cgmp-documentation-requirements-609a4915047af303PharmaRadar360en2026-09-18T16:35:47.000ZCan AI Agents Satisfy CGMP Documentation Requirements?https://www.pharmaradar360.com/article/dallas-clinical-research-unit-sponsor-overview-f49234afe6268753PharmaRadar360en2026-09-18T16:33:15.000ZDallas Clinical Research Unit: Sponsor overviewhttps://www.pharmaradar360.com/article/4-biotech-stocks-to-watch-as-potential-takeover-targets-471a060d652d759aPharmaRadar360en2026-09-18T16:31:00.000Z4 Biotech Stocks to Watch as Potential Takeover Targetshttps://www.pharmaradar360.com/article/when-ev-dose-is-not-what-it-seems-quantitative-mismatch-between-particle-number-f47a7c5a1a3284b4PharmaRadar360en2026-09-18T16:29:38.000ZWhen EV Dose Is Not What It Seems: Quantitative Mismatch Between Particle Number- and Protein-Based Dosinghttps://www.pharmaradar360.com/article/semi-mechanistic-joint-population-pharmacokinetic-modeling-of-the-novel-antitube-ebec18c2810c96c6PharmaRadar360en2026-09-18T16:02:31.000ZSemi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteershttps://www.pharmaradar360.com/article/frazier-life-sciences-adds-1-1b-to-biotech-fund-84639908b0e2b140PharmaRadar360en2026-09-18T15:50:57.000ZFrazier Life Sciences Adds $1.1B to Biotech Fundhttps://www.pharmaradar360.com/article/biotech-options-buzz-uthr-nmra-ewtx-904141373556fd38PharmaRadar360en2026-09-18T15:46:04.000ZBiotech Options Buzz: UTHR, NMRA, EWTXhttps://www.pharmaradar360.com/article/all-50-states-sign-up-for-trump-s-medicaid-most-favored-nation-plan-770767e418ae8a3aPharmaRadar360en2026-09-18T15:41:51.000ZAll 50 states sign up for Trump’s Medicaid most-favored-nation planhttps://www.pharmaradar360.com/article/do-you-have-to-be-bilingual-to-participate-in-circle-u-activities-c8b706a758c482a8PharmaRadar360en2026-09-18T15:39:27.000ZDo you have to be bilingual to participate in Circle U. activitieshttps://www.pharmaradar360.com/article/roche-expands-its-boston-footprint-with-new-research-center-61c8eaa9d2c59da9PharmaRadar360en2026-09-18T15:33:37.000ZRoche expands its Boston footprint with new research centerhttps://www.pharmaradar360.com/article/definium-trial-suggests-lsd-could-help-treat-anxiety-one-patient-meets-god-the-o-cb4c52a47721d100PharmaRadar360en2026-09-18T15:30:35.000ZDefinium trial suggests LSD could help treat anxiety; “One patient meets God. The other gets itchy.”; and Compass funds psilocybin-assisted therapist traininghttps://www.pharmaradar360.com/article/emirates-biotech-and-partner-launch-uae-organic-waste-to-biogas-pilot-7528d116c86d5b63PharmaRadar360en2026-09-18T15:24:56.000ZEmirates Biotech and partner launch UAE organic waste-to-biogas pilothttps://www.pharmaradar360.com/article/refreshed-novo-corrals-3-new-early-stage-obesity-drugs-from-kallyope-40f3fb0496b9f73ePharmaRadar360en2026-09-18T15:23:00.000ZRefreshed Novo corrals 3 new early-stage obesity drugs from Kallyopehttps://www.pharmaradar360.com/article/how-circle-u-helped-me-define-my-career-path-81b7d487eea3e910PharmaRadar360en2026-09-18T15:21:13.000ZHow Circle U. helped me define my career pathhttps://www.pharmaradar360.com/article/this-week-in-charts-gsk-s-china-deals-the-300m-ipo-club-and-selling-the-news-136aee8ad04163b2PharmaRadar360en2026-09-18T15:17:47.000ZThis week in charts: GSK’s China deals, the $300M IPO club and selling the newshttps://www.pharmaradar360.com/article/cordis-project-metabolic-disease-heterogeneity-definition-prevention-and-remissi-02382b733dd4e87cPharmaRadar360en2026-09-18T15:12:02.000ZCORDIS project: Metabolic disease heterogeneity definition, prevention and remission with targeted interventionshttps://www.pharmaradar360.com/article/cordis-project-next-generation-therapeutics-for-vascular-diseases-3a4c8847c4d7458ePharmaRadar360en2026-09-18T15:11:56.000ZCORDIS project: Next-generation therapeutics for vascular diseaseshttps://www.pharmaradar360.com/article/addressing-the-treatment-gap-in-cannabis-use-disorder-ad222fb9336b9389PharmaRadar360en2026-09-18T15:09:43.000ZAddressing the Treatment Gap in Cannabis Use Disorderhttps://www.pharmaradar360.com/article/novartis-receives-positive-chmp-opinion-for-cosentyx-in-polymyalgia-rheumatica-p-72f0f6aa86cf0f0bPharmaRadar360en2026-09-18T15:04:43.000ZNovartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)https://www.pharmaradar360.com/article/how-ai-biotech-and-personalization-are-reshaping-the-beauty-industry-by-2030-932bc402d6e4135fPharmaRadar360en2026-09-18T15:04:37.000ZHow AI, biotech and personalization are reshaping the beauty industry by 2030https://www.pharmaradar360.com/article/european-adrs-slip-in-us-trading-as-biotech-splits-5d79b846c95a7a75PharmaRadar360en2026-09-18T15:00:13.000ZEuropean ADRs Slip In US Trading As Biotech Splitshttps://www.pharmaradar360.com/article/37-000-ai-agents-are-running-a-virtual-biotech-at-stanford-486a0da87125e24aPharmaRadar360en2026-09-18T14:52:51.000Z37,000 AI Agents Are Running a Virtual Biotech at Stanfordhttps://www.pharmaradar360.com/article/weekly-buzz-rare-bayry-win-approvals-sion-cuts-jobs-gsk-deals-azn-rhhby-lead-6f672e18822611c2PharmaRadar360en2026-09-18T14:44:00.000ZWeekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Leadhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-sees-large-volume-increase-after-analyst-u-02e90aaa7ef82c7cPharmaRadar360en2026-09-18T14:42:34.000ZUltragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase After Analyst Upgradehttps://www.pharmaradar360.com/article/how-rebate-timing-distorts-a-pharmacy-s-340b-books-3fc20171d90a422cPharmaRadar360en2026-09-18T14:41:40.000ZHow Rebate Timing Distorts a Pharmacy's 340B Bookshttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-price-target-raised-to-32-00-e4b617ea41d02a41PharmaRadar360en2026-09-18T14:38:33.000ZUltragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $32.00https://www.pharmaradar360.com/article/guidance-covid-19-test-validation-approved-products-8740f36d3b2718d0PharmaRadar360en2026-09-18T14:38:10.000ZGuidance: COVID-19 test validation approved productshttps://www.pharmaradar360.com/article/biotech-catalyst-stocks-with-binary-events-coming-up-0e77c7de51362b23PharmaRadar360en2026-09-18T14:36:13.000ZBiotech catalyst stocks with binary events coming uphttps://www.pharmaradar360.com/article/fda-approves-first-gene-therapy-for-sanfilippo-syndrome-type-a-ddacc8fe3f2a7e07PharmaRadar360en2026-09-18T14:32:42.000ZFDA approves first gene therapy for Sanfilippo syndrome type Ahttps://www.pharmaradar360.com/article/spn-exclusive-an-early-look-at-mcc-s-completed-3-million-biotech-lab-68ba636d342ac5cfPharmaRadar360en2026-09-18T14:30:00.000ZSPN Exclusive: An early look at MCC’s completed $3 million biotech labhttps://www.pharmaradar360.com/article/fda-approves-pixclara-first-fet-pet-agent-for-glioma-imaging-29a803462ba6b015PharmaRadar360en2026-09-18T14:30:00.000ZFDA Approves Pixclara, First FET-PET Agent for Glioma Imaginghttps://www.pharmaradar360.com/article/q-a-how-can-sponsors-respond-to-clinical-trial-customs-delays-6f1b84efeb049467PharmaRadar360en2026-09-18T14:24:16.000ZQ&A: How Can Sponsors Respond to Clinical Trial Customs Delays?https://www.pharmaradar360.com/article/ufrj-debate-defesa-da-democracia-confrontos-e-estrategias-de-comunicacao-em-reun-9eb7532f7d41d72aPharmaRadar360en2026-09-18T14:23:57.000ZUFRJ debate defesa da democracia, confrontos e estratégias de comunicação em reunião com professores eméritoshttps://www.pharmaradar360.com/article/fierce-pharma-asia-china-deals-safe-from-coins-key-wclc-data-legend-s-new-ceo-c23fdc3b607774daPharmaRadar360en2026-09-18T14:20:52.000ZFierce Pharma Asia—China deals safe from COINS?; Key WCLC data; Legend’s new CEOhttps://www.pharmaradar360.com/article/introducing-the-pharmtech-ai-pulse-check-expert-video-series-c9a61784abb684dePharmaRadar360en2026-09-18T14:20:07.000ZIntroducing the "PharmTech AI Pulse Check" Expert Video Serieshttps://www.pharmaradar360.com/article/aard-investor-alert-aardvark-therapeutics-inc-securities-class-action-notice-con-b0fff291ba5a6cc1PharmaRadar360en2026-09-18T14:09:00.000ZAARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinskyhttps://www.pharmaradar360.com/article/nordic-perspectives-on-education-a-two-book-launch-335960b186ef8c7dPharmaRadar360en2026-09-18T14:06:32.000ZNordic Perspectives on Education: A Two-Book Launchhttps://www.pharmaradar360.com/article/virtual-biotech-ai-system-advances-drug-discovery-with-37-000-agents-6df6d3ca1fbffbc8PharmaRadar360en2026-09-18T14:01:42.000ZVirtual Biotech AI System Advances Drug Discovery with 37,000 Agentshttps://www.pharmaradar360.com/article/a-closer-look-at-the-50-billion-rural-health-transformation-program-76a13771919bcee8PharmaRadar360en2026-09-18T14:00:00.000ZA Closer Look at the $50 Billion Rural Health Transformation Programhttps://www.pharmaradar360.com/article/bucks-county-biotech-hub-and-doylestown-hospital-land-state-grants-for-new-proje-8665c163a0e7a8bcPharmaRadar360en2026-09-18T14:00:00.000ZBucks County Biotech Hub and Doylestown Hospital Land State Grants for New Projectshttps://www.pharmaradar360.com/article/regional-signaling-controls-stem-cell-mediated-regeneration-in-an-invertebrate-c-04c94807eadc3cd8PharmaRadar360en2026-09-18T14:00:00.000ZRegional signaling controls stem cell-mediated regeneration in an invertebrate chordatehttps://www.pharmaradar360.com/article/collagen-i-promotes-cancer-cell-survival-via-amino-acid-import-and-mtorc1-s6-act-8a92da132dac0e52PharmaRadar360en2026-09-18T14:00:00.000ZCollagen I promotes cancer cell survival via amino acid import and mTORC1/S6 activationhttps://www.pharmaradar360.com/article/novo-targets-oral-macrocycles-with-1-4bn-orbis-partnership-6671ed6a26e6a1c2PharmaRadar360en2026-09-18T13:52:36.000ZNovo targets oral macrocycles with $1.4bn Orbis partnershiphttps://www.pharmaradar360.com/article/le-chu-de-toulouse-debute-les-inclusions-dans-l-etude-impulsion-41595d44ba4dcd69PharmaRadar360en2026-09-18T13:47:41.000ZLe CHU de Toulouse débute les inclusions dans l'étude IMPULSIONhttps://www.pharmaradar360.com/article/what-is-drawing-fresh-attention-to-takeda-pharmaceutical-tse-4502-8ed4853f5f8b35ebPharmaRadar360en2026-09-18T13:44:21.000ZWhat Is Drawing Fresh Attention To Takeda Pharmaceutical (TSE:4502)?https://www.pharmaradar360.com/article/inside-the-growing-world-of-biopharma-prediction-markets-765a66b0e486f7ccPharmaRadar360en2026-09-18T13:39:41.000ZInside the growing world of biopharma prediction marketshttps://www.pharmaradar360.com/article/veradermics-buy-before-the-catalysts-nyse-mane-90826b45a2962049PharmaRadar360en2026-09-18T13:39:00.000ZVeradermics: Buy Before The Catalysts (NYSE:MANE)https://www.pharmaradar360.com/article/shingles-can-cause-severe-chronic-pain-new-research-on-how-exosomes-alter-neuron-2a6301bdbff0f775PharmaRadar360en2026-09-18T13:33:48.000ZShingles Can Cause Severe Chronic Pain – New Research On How Exosomes Alter Neurons Offers Pathways To Treatmenthttps://www.pharmaradar360.com/article/4-westchester-fairfield-leaders-advocate-for-health-and-raise-funds-critical-for-78121da21d239558PharmaRadar360en2026-09-18T13:29:00.000Z4 Westchester/Fairfield leaders advocate for health and raise funds critical for fighting heart diseasehttps://www.pharmaradar360.com/article/seqens-brings-its-personal-care-and-custom-specialties-activities-together-withi-48e0fd6157eea57ePharmaRadar360en2026-09-18T13:27:31.000ZSEQENS brings its Personal Care and Custom & Specialties activities together within a single organization.https://www.pharmaradar360.com/article/reasons-to-add-west-pharmaceutical-stock-to-your-portfolio-now-a987741149fa9bd2PharmaRadar360en2026-09-18T13:21:00.000ZReasons to Add West Pharmaceutical Stock to Your Portfolio Nowhttps://www.pharmaradar360.com/article/suny-funding-to-advance-tech-that-could-improve-patient-care-9e34ce94de8cee0fPharmaRadar360en2026-09-18T13:15:09.000ZSUNY funding to advance tech that could improve patient carehttps://www.pharmaradar360.com/article/biotech-pre-market-movers-tcrt-meds-surge-xene-nuwe-sink-caabe3a95f74fd25PharmaRadar360en2026-09-18T13:13:00.000ZBiotech Pre-Market Movers: TCRT, MEDS Surge; XENE, NUWE Sinkhttps://www.pharmaradar360.com/article/aces-alumna-employs-biotech-to-create-sustainable-livestock-production-bcccea6733969c2cPharmaRadar360en2026-09-18T13:12:17.000ZACES alumna employs biotech to create sustainable livestock productionhttps://www.pharmaradar360.com/article/stanford-virtual-biotech-links-target-expression-patterns-to-higher-drug-success-4f2cc92095f808d2PharmaRadar360en2026-09-18T13:04:57.000ZStanford Virtual Biotech links target expression patterns to higher drug successhttps://www.pharmaradar360.com/article/state-fiscal-conditions-context-on-medicaid-budgets-for-fy-2027-a4d0ffddaeb7db7dPharmaRadar360en2026-09-18T13:00:00.000ZState Fiscal Conditions: Context on Medicaid Budgets for FY 2027https://www.pharmaradar360.com/article/chutes-ladders-legend-poaches-novartis-vet-to-boost-commercial-potential-e80965543b112e35PharmaRadar360en2026-09-18T12:53:06.000ZChutes & Ladders—Legend poaches Novartis vet to boost commercial potentialhttps://www.pharmaradar360.com/article/auszeichnungen-fur-herausragende-forschung-und-innovation-in-der-infektiologie-2e2b4d68c515c033PharmaRadar360en2026-09-18T12:46:20.000ZAuszeichnungen für herausragende Forschung und Innovation in der Infektiologiehttps://www.pharmaradar360.com/article/canaccord-genuity-group-increases-ultragenyx-pharmaceutical-nasdaq-rare-price-ta-7cfbe3170174b2c9PharmaRadar360en2026-09-18T12:45:11.000ZCanaccord Genuity Group Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $39.00https://www.pharmaradar360.com/article/west-pharma-to-cut-98-jobs-as-smartdose-production-winds-down-in-arizona-47ebb0bb9de0baddPharmaRadar360en2026-09-18T12:35:00.000ZWest Pharma to cut 98 jobs as SmartDose production winds down in Arizonahttps://www.pharmaradar360.com/article/unc-global-affairs-encourages-more-study-abroad-in-japan-b882c10bbd673b89PharmaRadar360en2026-09-18T12:34:51.000ZUNC Global Affairs encourages more study abroad in Japanhttps://www.pharmaradar360.com/article/scientists-discover-cells-that-cheat-death-and-rebuild-damaged-tissue-2ba232951401badcPharmaRadar360en2026-09-18T12:30:43.000ZScientists discover cells that cheat death and rebuild damaged tissuehttps://www.pharmaradar360.com/article/abbvie-highlights-new-real-world-data-supporting-the-effectiveness-of-vraylar-ca-4c1f376b38b218c5PharmaRadar360en2026-09-18T12:30:00.000ZAbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026https://www.pharmaradar360.com/article/lakewood-amedex-starts-phase-2a-trial-for-nu-3-to-treat-diabetic-foot-ulcers-wit-e4b94f11fe4c68f0PharmaRadar360en2026-09-18T12:24:15.000ZLakewood-Amedex starts Phase 2a trial for Nu-3 to treat diabetic foot ulcers with drug-resistant infectionshttps://www.pharmaradar360.com/article/jahresbericht-des-krebsregisters-der-kantone-zurich-zug-schaffhausen-und-schwyz-63636ce70813c644PharmaRadar360en2026-09-18T12:14:30.000ZJahresbericht des Krebsregisters der Kantone Zürich, Zug, Schaffhausen und Schwyzhttps://www.pharmaradar360.com/article/cantor-fitzgerald-forecasts-strong-price-appreciation-for-ultragenyx-pharmaceuti-a94686663212042bPharmaRadar360en2026-09-18T12:13:08.000ZCantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stockhttps://www.pharmaradar360.com/article/a-new-gel-for-infected-diabetic-foot-ulcers-is-ready-for-a-clinical-trial-9baca5ba6094011dPharmaRadar360en2026-09-18T12:13:00.000ZA new gel for infected diabetic foot ulcers is ready for a clinical trialhttps://www.pharmaradar360.com/article/lakewood-amedex-biotherapeutics-announces-irb-approval-and-clinical-site-readine-6c633ac91c89ca34PharmaRadar360en2026-09-18T12:13:00.000ZLakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcershttps://www.pharmaradar360.com/article/ligand-pharmaceuticals-owning-it-gives-you-a-stake-across-biotech-nasdaq-lgnd-a5490902b4f252f8PharmaRadar360en2026-09-18T12:06:16.000ZLigand Pharmaceuticals: Owning It Gives You A Stake Across Biotech (NASDAQ:LGND)https://www.pharmaradar360.com/article/countering-motor-neuron-degeneration-with-base-editing-155eca28b20c8601PharmaRadar360en2026-09-18T12:00:00.000ZCountering Motor Neuron Degeneration with Base Editinghttps://www.pharmaradar360.com/article/establishment-of-two-new-on-site-laboratories-approved-465c999c4a9c1229PharmaRadar360en2026-09-18T12:00:00.000ZEstablishment of two new On-site Laboratories approvedhttps://www.pharmaradar360.com/article/signatm-artist-and-signatm-artist-evo-b43f2d2ea4307776PharmaRadar360en2026-09-18T12:00:00.000ZSIGNA™ Artist and SIGNA™ Artist Evohttps://www.pharmaradar360.com/article/counterfeit-laser-hair-removal-and-therapy-devices-found-in-some-clinics-and-may-48182ef1961b6594PharmaRadar360en2026-09-18T12:00:00.000ZCounterfeit laser hair removal and therapy devices found in some clinics and may pose serious health riskshttps://www.pharmaradar360.com/article/ukri-space-lab-hosts-first-uk-pm-and-head-of-nato-meeting-484a0b72310be070PharmaRadar360en2026-09-18T11:33:37.000ZUKRI Space Lab hosts first UK PM and Head of NATO meetinghttps://www.pharmaradar360.com/article/abeona-therapeutics-congratulates-ultragenyx-on-u-s-fda-approval-of-fayuvitm-gen-08da3da710ebe595PharmaRadar360en2026-09-18T11:30:00.000ZAbeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)https://www.pharmaradar360.com/article/das-universitatsklinikum-heidelberg-ist-grundungsmitglied-von-medi-cus-bff2845ac3e34d06PharmaRadar360en2026-09-18T11:29:44.000ZDas Universitätsklinikum Heidelberg ist Gründungsmitglied von MEDI:CUShttps://www.pharmaradar360.com/article/china-unveils-a-new-five-year-plan-for-developing-pharmaceutical-industry-44919095069d11e6PharmaRadar360en2026-09-18T11:14:00.000ZChina unveils a new five-year plan for developing pharmaceutical industryhttps://www.pharmaradar360.com/article/pune-fda-action-rodent-droppings-live-cockroaches-found-in-new-poona-club-kitche-bb758074ecbcb628PharmaRadar360en2026-09-18T11:12:49.000ZPune FDA Action: Rodent Droppings, Live Cockroaches Found In New Poona Club Kitchen; Food Licence Suspendedhttps://www.pharmaradar360.com/article/why-executive-mfn-deals-aren-t-enough-q-a-with-joe-cunningham-48c869a29e6c3e7fPharmaRadar360en2026-09-18T11:10:17.000ZWhy Executive MFN Deals Aren't Enough: Q&A with Joe Cunninghamhttps://www.pharmaradar360.com/article/addressing-mfn-innovation-concerns-568aea26781afe55PharmaRadar360en2026-09-18T11:10:17.000ZAddressing MFN Innovation Concernshttps://www.pharmaradar360.com/article/shining-a-light-on-uterine-cancer-rising-incidence-and-mortality-persistent-ineq-b6df0ffb13807c1dPharmaRadar360en2026-09-18T11:00:17.000ZShining a Light on Uterine Cancer: Rising Incidence and Mortality, Persistent Inequitieshttps://www.pharmaradar360.com/article/bristol-myers-squibb-to-report-results-for-third-quarter-2026-on-october-29-2026-915d65a4fe2302cbPharmaRadar360en2026-09-18T10:59:00.000ZBristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026https://www.pharmaradar360.com/article/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say-9eef7f5883b17b66PharmaRadar360en2026-09-18T10:55:03.000ZExclusive-US weighs allowing most pharma licensing deals with China, sources sayhttps://www.pharmaradar360.com/article/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-padcev-e-9dda3e8e04d1e9eaPharmaRadar360en2026-09-18T10:55:00.000ZMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)https://www.pharmaradar360.com/article/chmp-recommends-eu-approval-of-roche-s-ocrevus-for-children-and-adolescents-with-7987b36e70396aa4PharmaRadar360en2026-09-18T10:45:00.000ZCHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosishttps://www.pharmaradar360.com/article/merck-launches-your-hive-of-whole-health-to-support-whole-person-care-for-people-6fb49d94bbe3b4f2PharmaRadar360en2026-09-18T10:45:00.000ZMerck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIVhttps://www.pharmaradar360.com/article/china-targets-3-5-trillion-yuan-pharmaceutical-industry-by-2030-ea3e6220b6b84bbfPharmaRadar360en2026-09-18T10:37:00.000ZChina Targets 3.5 Trillion Yuan Pharmaceutical Industry by 2030https://www.pharmaradar360.com/article/drugs-and-devices-reach-patients-before-required-safety-studies-finish-and-feder-548b50c37e1139d5PharmaRadar360en2026-09-18T10:31:07.000ZDrugs and Devices Reach Patients Before Required Safety Studies Finish and Federal Records Show Many Run Latehttps://www.pharmaradar360.com/article/a-sellas-immunotherapy-study-long-delayed-will-end-in-failure-4f39356374c8bccbPharmaRadar360en2026-09-18T10:28:36.000ZA Sellas immunotherapy study, long delayed, will end in failurehttps://www.pharmaradar360.com/article/investors-pour-over-30b-into-longevity-biotech-companies-8159bc55d8a873cePharmaRadar360en2026-09-18T10:15:47.000ZInvestors pour over $30B into longevity biotech companieshttps://www.pharmaradar360.com/article/nuvectis-pharma-haisco-licensing-deal-revitalises-biotech-but-no-rush-to-invest-9e5025881f0236a4PharmaRadar360en2026-09-18T10:15:05.000ZNuvectis Pharma:Haisco Licensing Deal Revitalises Biotech, But No Rush To Invest Now(NVCT)https://www.pharmaradar360.com/article/chicago-biotech-inomagen-lands-up-to-2-9m-for-gene-therapy-targeting-afib-2314e0a3b1c7a48dPharmaRadar360en2026-09-18T10:15:00.000ZChicago biotech Inomagen lands up to $2.9M for gene therapy targeting AFibhttps://www.pharmaradar360.com/article/investors-pour-over-30b-into-longevity-biotech-companies-fe16e000e0bbdcc4PharmaRadar360en2026-09-18T10:13:53.000ZInvestors pour over $30B into longevity biotech companieshttps://www.pharmaradar360.com/article/market-movers-rx-west-pharmaceutical-services-leads-gainers-d11ab73a9d464311PharmaRadar360en2026-09-18T10:10:17.000ZMarket Movers RX: West Pharmaceutical Services Leads Gainershttps://www.pharmaradar360.com/article/understanding-the-latest-with-mfn-pricing-and-what-it-means-to-pharma-611640f35e9de0d0PharmaRadar360en2026-09-18T10:10:17.000ZUnderstanding the Latest with MFN Pricing and What It Means to Pharmahttps://www.pharmaradar360.com/article/novartis-india-acquires-pfizer-s-minipress-brands-for-150-million-717f175a2a74699dPharmaRadar360en2026-09-18T10:04:35.000ZNovartis India acquires Pfizer’s Minipress brands for $150 millionhttps://www.pharmaradar360.com/article/alterity-therapeutics-nasdaq-athe-to-outline-msa-drug-plans-at-asx-smidcaps-conf-1fca461c030238b6PharmaRadar360en2026-09-18T10:03:29.000ZAlterity Therapeutics (NASDAQ: ATHE) to outline MSA drug plans at ASX SMIDcaps conferencehttps://www.pharmaradar360.com/article/xenon-pauses-phase-3-depression-trials-after-psychosis-events-c474442598d818f4PharmaRadar360en2026-09-18T10:03:00.000ZXenon pauses phase 3 depression trials after psychosis eventshttps://www.pharmaradar360.com/article/clear-labels-act-stripped-of-key-provisions-before-senate-vote-81d6841a7d217e7cPharmaRadar360en2026-09-18T10:00:00.000ZCLEAR LABELS Act stripped of key provisions before Senate votehttps://www.pharmaradar360.com/article/a-clear-watering-down-drug-transparency-bill-stripped-of-critical-provisions-ahe-5a903264c20ac795PharmaRadar360en2026-09-18T10:00:00.000Z“A Clear Watering Down”: Drug Transparency Bill Stripped of Critical Provisions Ahead of Senate Votehttps://www.pharmaradar360.com/article/the-key-to-success-is-being-willing-to-understand-the-energy-system-9887c5050e48720dPharmaRadar360en2026-09-18T09:57:06.000Z‘The key to success is being willing to understand the energy system’https://www.pharmaradar360.com/article/these-blood-thinners-may-have-an-unexpected-benefit-for-alzheimer-s-patients-daa8fc27301148bfPharmaRadar360en2026-09-18T09:48:31.000ZThese blood thinners may have an unexpected benefit for Alzheimer’s patientshttps://www.pharmaradar360.com/article/cantor-fitzgerald-maintains-overweight-rating-on-ultragenyx-pharmaceutical-39-pr-90bfb8ef4162d81ePharmaRadar360en2026-09-18T09:41:18.000ZCantor Fitzgerald maintains Overweight rating on Ultragenyx Pharmaceutical, $39 price targethttps://www.pharmaradar360.com/article/novo-bets-on-ai-designed-macrocycles-in-orbis-oral-drugs-deal-3d2fb0a79abc2e12PharmaRadar360en2026-09-18T09:28:45.000ZNovo bets on AI-designed macrocycles in Orbis oral drugs dealhttps://www.pharmaradar360.com/article/grunenthal-prices-850m-euros-of-notes-to-refinance-and-fund-expansion-51639ee1c0a91b88PharmaRadar360en2026-09-18T09:24:14.000ZGrünenthal prices 850m euros of notes to refinance and fund expansionhttps://www.pharmaradar360.com/article/rapport-therapeutics-inc-rapp-stock-analysis-a-clinical-stage-biotech-with-a-49-bb04e31254be6de9PharmaRadar360en2026-09-18T09:19:49.000ZRapport Therapeutics, Inc. (RAPP) Stock Analysis: A Clinical-Stage Biotech with a 49.90% Upside Potentialhttps://www.pharmaradar360.com/article/celcuity-inc-celc-stock-analysis-unpacking-an-89-32-potential-upside-in-biotech-ed1c905c6f09d8a1PharmaRadar360en2026-09-18T09:19:25.000ZCelcuity Inc. (CELC) Stock Analysis: Unpacking An 89.32% Potential Upside In Biotechhttps://www.pharmaradar360.com/article/oruka-therapeutics-inc-orka-stock-analysis-a-58-6-potential-upside-beckons-biote-d636f4afe1bf33f2PharmaRadar360en2026-09-18T09:19:23.000ZOruka Therapeutics, Inc. (ORKA) Stock Analysis: A 58.6% Potential Upside Beckons Biotech Investorshttps://www.pharmaradar360.com/article/oric-pharmaceuticals-oric-stock-analysis-a-60-upside-potential-with-strong-buy-r-8623ff2cd166514bPharmaRadar360en2026-09-18T09:19:20.000ZOric Pharmaceuticals (ORIC) Stock Analysis: A 60% Upside Potential with Strong Buy Ratings in Biotechhttps://www.pharmaradar360.com/article/primo-capital-launches-biotech-venture-fund-for-italy-s-lazio-region-b6ff7a9c7111e9f9PharmaRadar360en2026-09-18T09:09:55.000ZPrimo Capital launches biotech venture fund for Italy's Lazio regionhttps://www.pharmaradar360.com/article/a-journey-to-self-discovery-the-story-of-a-circle-u-student-fellow-5fea8b858725c8aePharmaRadar360en2026-09-18T09:06:34.000ZA journey to self discovery – the story of a Circle U. Student Fellowhttps://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-f50b3d6ed1b0bc0dPharmaRadar360en2026-09-18T09:03:49.000ZThe Drugs and Devices Have Been on the Market for Years. But FDA-Ordered Studies Still Aren’t Done.https://www.pharmaradar360.com/article/the-specter-of-ai-enabled-bioweapons-is-a-wake-up-call-for-biotech-f0e619b6ad1a6523PharmaRadar360en2026-09-18T09:00:00.000ZThe specter of AI-enabled bioweapons is a wake-up call for biotechhttps://www.pharmaradar360.com/article/decision-marketing-authorisations-granted-in-2026-0fc9c2c1015a12a7PharmaRadar360en2026-09-18T08:52:31.000ZDecision: Marketing authorisations Granted in 2026https://www.pharmaradar360.com/article/decision-parallel-import-licences-granted-in-2026-f337a3e18a403d26PharmaRadar360en2026-09-18T08:52:27.000ZDecision: Parallel import licences granted in 2026https://www.pharmaradar360.com/article/lb-pharmaceuticals-rated-buy-with-85-base-value-150-potential-if-phase-3-succeed-9332fe094c538a69PharmaRadar360en2026-09-18T08:46:20.000ZLB Pharmaceuticals rated buy with $85 base value, $150 potential if Phase 3 succeeds by 2027https://www.pharmaradar360.com/article/mhra-consultation-on-statutory-fees-2026-4e7ecd381fcc9a03PharmaRadar360en2026-09-18T08:45:02.000ZMHRA consultation on statutory fees (2026)https://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-mnov-36-pbls-10-abcl-9-hae-neo-140ed34b93773a97PharmaRadar360en2026-09-18T08:36:00.000ZBiotech Stocks At 52-Week Highs - MNOV +36%, PBLS +10%, ABCL +9%, HAE, NEOhttps://www.pharmaradar360.com/article/boehringer-discontinues-phase-iii-easi-kidney-trial-of-vicadrostat-5d694399009054c9PharmaRadar360en2026-09-18T08:35:26.000ZBoehringer discontinues Phase III EASi-KIDNEY trial of vicadrostathttps://www.pharmaradar360.com/article/dimerix-asx-dxb-action3-kidney-disease-trial-remains-central-to-development-path-aa84609d9f537b5bPharmaRadar360en2026-09-18T08:34:00.000ZDimerix (ASX:DXB): ACTION3 Kidney Disease Trial Remains Central to Development Pathhttps://www.pharmaradar360.com/article/hexavalent-combination-vaccine-programme-guidance-83f6b178f952c923PharmaRadar360en2026-09-18T08:30:02.000ZHexavalent combination vaccine: programme guidancehttps://www.pharmaradar360.com/article/0366002724-ur-test-120ml-sterile-108d430e0a4ba326PharmaRadar360en2026-09-18T08:14:32.000ZΑνάκληση της παρτίδας 0366002724 του Ιατροτεχνολογικού προϊόντος UR-TEST 120ml Sterile Ουροσυλλέκτηςhttps://www.pharmaradar360.com/article/vendanges-sur-le-site-hospitalier-des-hus-de-la-robertsau-pour-les-residents-de-c010efcb07425afdPharmaRadar360en2026-09-18T08:13:19.000ZVendanges sur le site hospitalier des HUS de la Robertsau pour les résidents de l’EHPAD : héritage patrimonial et lien intergénérationnelhttps://www.pharmaradar360.com/article/a-guide-to-sarms-definition-side-effects-and-dangers-e67630b4d57afdc1PharmaRadar360en2026-09-18T08:00:59.000ZA Guide to SARMs: Definition, Side Effects, and Dangershttps://www.pharmaradar360.com/article/biomedicine-powerhouse-china-targets-quarter-of-global-first-in-class-drugs-6b7e17dcbf9db5c6PharmaRadar360en2026-09-18T08:00:06.000ZBiomedicine powerhouse: China targets quarter of global first-in-class drugshttps://www.pharmaradar360.com/article/herzmedizin-und-anatomie-beim-festival-der-wissenschaft-und-neugier-ae5897933fcd4fa9PharmaRadar360en2026-09-18T07:42:16.000ZHerzmedizin und Anatomie beim „Festival der Wissenschaft und Neugier“https://www.pharmaradar360.com/article/bms-dumps-100m-orum-degrader-antibody-conjugate-after-glimpsing-phase-1-data-24ceb75fbe9947cePharmaRadar360en2026-09-18T07:41:37.000ZBMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 datahttps://www.pharmaradar360.com/article/trump-administration-shift-puts-this-corner-of-biotech-back-in-favor-9c761ffe135492bbPharmaRadar360en2026-09-18T07:28:36.000ZTrump Administration Shift Puts This Corner of Biotech Back in Favorhttps://www.pharmaradar360.com/article/why-i-keep-going-back-to-ukraine-during-wartime-df612d9b073be5dcPharmaRadar360en2026-09-18T07:26:33.000ZWhy I keep going back to Ukraine during wartimehttps://www.pharmaradar360.com/article/millimeterarbeit-gegen-lungentumoren-die-music-studie-53be2a6ee6a105b4PharmaRadar360en2026-09-18T07:14:56.000ZMillimeterarbeit gegen Lungentumoren: die MUSIC-Studiehttps://www.pharmaradar360.com/article/pawbio-animal-health-biologics-services-1a048e6660565241PharmaRadar360en2026-09-18T07:13:03.000ZPawBio Animal Health Biologics Serviceshttps://www.pharmaradar360.com/article/tumore-al-seno-in-humanitas-torna-paziente-diplomata-e54455d5d56e61c1PharmaRadar360en2026-09-18T07:03:41.000ZTumore al seno: in Humanitas torna “Paziente diplomata”https://www.pharmaradar360.com/article/chronisch-entzundliche-darmerkrankungen-im-fokus-a1687f02fff393f7PharmaRadar360en2026-09-18T07:03:18.000ZChronisch-entzündliche Darmerkrankungen im Fokushttps://www.pharmaradar360.com/article/unmc-brings-ems-professionals-to-omaha-for-training-4f1f1a30c9c75fcbPharmaRadar360en2026-09-18T07:00:00.000ZUNMC brings EMS professionals to Omaha for traininghttps://www.pharmaradar360.com/article/insilico-medicine-s-alex-zhavoronkov-bets-china-and-ai-can-deliver-the-drug-indu-bf58fc441aef28acPharmaRadar360en2026-09-18T07:00:00.000ZInsilico Medicine's Alex Zhavoronkov bets China and AI can deliver the drug industry’s next breakthroughhttps://www.pharmaradar360.com/article/anna-maria-fjordb-ge-discussed-ethnographic-findings-on-digitalisation-and-judic-741ca0d3539fbc98PharmaRadar360en2026-09-18T06:58:57.000ZAnna Maria Fjordbøge discussed ethnographic findings on digitalisation and judicial independencehttps://www.pharmaradar360.com/article/inflammation-biotech-electra-charges-up-with-350m-from-upsized-ipo-58f7ac98a3c81cd2PharmaRadar360en2026-09-18T06:58:51.000ZInflammation biotech Electra charges up with $350M from upsized IPOhttps://www.pharmaradar360.com/article/candidate-christy-knorr-tours-unmc-9c858ca4e9103a33PharmaRadar360en2026-09-18T06:58:00.000ZCandidate Christy Knorr tours UNMChttps://www.pharmaradar360.com/article/employee-giving-campaign-runs-through-sept-25-3d755fdad3d90840PharmaRadar360en2026-09-18T06:56:00.000ZEmployee Giving Campaign runs through Sept. 25https://www.pharmaradar360.com/article/dr-klepser-to-lead-session-on-culture-by-design-673f758cb628666cPharmaRadar360en2026-09-18T06:54:00.000ZDr. Klepser to lead session on ‘Culture by Design’https://www.pharmaradar360.com/article/unmc-for-the-record-sept-18-2026-26f128b25ad022fcPharmaRadar360en2026-09-18T06:50:00.000ZUNMC for the record, Sept. 18, 2026https://www.pharmaradar360.com/article/aspen-leader-shares-insights-on-advancing-healthcare-transformation-across-afric-e197406ab7edc88cPharmaRadar360en2026-09-18T06:40:19.000ZAspen leader shares insights on advancing healthcare transformation across Africahttps://www.pharmaradar360.com/article/foundationone-cdx-alk-9df8eafd03eb3fdaPharmaRadar360en2026-09-18T06:30:00.000ZFoundationOne CDx がんゲノムプロファイル、ALK融合遺伝子陽性の非小細胞肺癌に対するロルラチニブのコンパニオン診断として承認を取得https://www.pharmaradar360.com/article/chugai-obtains-approval-for-foundationone-cdx-cancer-genomic-profile-as-a-compan-a1b0d45f052647e4PharmaRadar360en2026-09-18T06:30:00.000ZChugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Lorlatinib for ALK Fusion Gene-Positive Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/otsuka-and-jolly-good-launch-new-content-for-faceduo-dementia-care-support-vr-un-2392b089dce1c64fPharmaRadar360en2026-09-18T06:00:00.000ZOtsuka and Jolly Good Launch New Content for FACEDUO Dementia Care Support VR Understanding a New Perspective on Dementiahttps://www.pharmaradar360.com/article/fete-de-la-science-2026-b279a061dcc65a5cPharmaRadar360en2026-09-18T06:00:00.000ZFête de la science 2026https://www.pharmaradar360.com/article/tissue-repair-asx-trp-phase-3-wound-healing-trial-remains-central-to-development-7287d50919577414PharmaRadar360en2026-09-18T05:55:00.000ZTissue Repair (ASX:TRP): Phase 3 Wound Healing Trial Remains Central to Development Pathhttps://www.pharmaradar360.com/article/china-unveils-15th-five-year-plan-for-pharmaceutical-industry-targeting-over-20-2ab6174a22012261PharmaRadar360en2026-09-18T05:55:00.000ZChina Unveils 15th Five-Year Plan for Pharmaceutical Industry, Targeting Over 20% Annual Revenue Growth in Innovative Drugshttps://www.pharmaradar360.com/article/department-of-energy-launches-215-million-race-to-build-quantum-computer-by-2028-041c6521fc4b9518PharmaRadar360en2026-09-18T05:50:00.000ZDepartment of Energy launches $215 million race to build quantum computer by 2028https://www.pharmaradar360.com/article/flu-vaccination-in-the-social-care-sector-63cb5603bb33eecdPharmaRadar360en2026-09-18T05:45:14.000ZFlu vaccination in the social care sectorhttps://www.pharmaradar360.com/article/the-latest-iphone-apple-watch-and-airpods-lineups-arrive-in-stores-worldwide-ec905d3774ad7d98PharmaRadar360en2026-09-18T05:02:14.000ZThe latest iPhone, Apple Watch, and AirPods lineups arrive in stores worldwidehttps://www.pharmaradar360.com/article/etra-ipo-news-antibody-biotech-electra-therapeutics-prices-upsized-ipo-at-15-mid-bd92cafd24c85550PharmaRadar360en2026-09-18T04:59:00.000ZETRA IPO News - Antibody biotech Electra Therapeutics prices upsized IPO at $15 midpointhttps://www.pharmaradar360.com/article/2026-7-10-15-943b204f7d94498aPharmaRadar360en2026-09-18T04:57:29.000Z2026年度 第7回東北大学病院がんセミナー開催のお知らせ（10/15開催）https://www.pharmaradar360.com/article/slv-revenue-fell-14-and-net-loss-widened-as-biotech-demand-dropped-but-drug-deve-44b2d4b9fcc80835PharmaRadar360en2026-09-18T04:55:00.000ZSLV: Revenue fell 14% and net loss widened as biotech demand dropped, but Drug Development grew 16%https://www.pharmaradar360.com/article/ultragenyx-shares-rise-after-hours-following-fda-approval-ultragenyx-pharmaceuti-4517cfdb85b67294PharmaRadar360en2026-09-18T04:26:40.000ZUltragenyx Shares Rise After Hours Following FDA Approval - Ultragenyx Pharmaceutical (NASDAQ:RARE)https://www.pharmaradar360.com/article/scientists-restore-a-brain-protein-and-reverse-signs-of-aging-in-mice-e17168fca74ee1f1PharmaRadar360en2026-09-18T04:25:45.000ZScientists restore a brain protein and reverse signs of aging in micehttps://www.pharmaradar360.com/article/satellite-reveals-a-world-of-weird-rivers-shaped-by-humans-742307336c51ecc0PharmaRadar360en2026-09-18T04:10:28.000ZSatellite reveals a world of ‘weird rivers’ shaped by humanshttps://www.pharmaradar360.com/article/mumbai-fda-suspends-food-licences-of-seven-eateries-over-safety-violations-9073bad5e1dd6410PharmaRadar360en2026-09-18T04:07:40.000ZMumbai FDA suspends food licences of seven eateries over safety violations